For Immediate Release For Further Information Contact: Andrew Fisher at (301) 608-9292 Email: afisher@unither.com

STUART RICH, M.D. JOINS UNITED THERAPEUTICS AS CHIEF MEDICAL OFFICER

Silver Spring, MD, October 7, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that Stuart Rich, M.D. will serve as its Chief Medical Officer, effective January 1, 2004.

"We are honored that a physician and scientist of Stuart Rich's stature will become our Chief Medical Officer," said Martine Rothblatt, United Therapeutics' Chairman and CEO. "Dr. Rich's successful work in proving the survival advantages of warfarin, calcium channel blockers, and Flolan® for pulmonary arterial hypertension patients makes him eminently qualified to lead our intravenous Remodulin® program for patients who do not respond to oral medications."

Dr. Rich will continue on a part-time basis as Professor of Medicine and Director of the Rush Heart Institute Center for Pulmonary Heart Disease at Rush Presbyterian-St. Luke's Medical Center, the country's largest referral center for patients with pulmonary hypertension. Dr. Rich is a fellow of the American College of Cardiology, the American Heart Association, the American College of Physicians, and the American College of Chest Physicians. He is a member of the Scientific Leadership Council of the Pulmonary Hypertension Association, a member of the editorial board of the Journal of the American College of Cardiology, and a consultant for 38 other medical and scientific journals. Dr. Rich has received over 45 research grants including funding from the National Institutes of Health and the American Heart Association. He has published over 300 scientific manuscripts, abstracts and book chapters.

"I am very pleased to join United Therapeutics because of its commitment to science and medicine," said Dr. Rich. "The company's pioneering efforts to develop new therapies for pulmonary hypertension and other life-threatening conditions have helped to improve the quality of life for patients worldwide, while providing clinicians with an excellent example of an ethical pharmaceutical company."

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *